AstraZeneca’s Diabetes Combo Could Help Stake Its Independence From Pfizer
This article was originally published in The Pink Sheet Daily
Executive Summary
Positive trial results buoy the British pharma’s late-stage pipeline as it battles to keep its independence from Pfizer. The saxagliptin/dapagliflozin combo is a cornerstone of the diabetes franchise.